These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. Tateo V, Manuzzi L, De Giglio A, Parisi C, Lamberti G, Campana D, Pantaleo MA. Int J Mol Sci; 2020 Nov 28; 21(23):. PubMed ID: 33260538 [Abstract] [Full Text] [Related]
3. Understanding the landscape of immunotherapy in thymic epithelial tumors. Maniar R, Loehrer PJ. Cancer; 2023 Apr 15; 129(8):1162-1172. PubMed ID: 36808725 [Abstract] [Full Text] [Related]
4. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies. Lippner EA, Lewis DB, Robinson WH, Katsumoto TR. Curr Treat Options Oncol; 2019 Jun 22; 20(7):62. PubMed ID: 31227926 [Abstract] [Full Text] [Related]
5. Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. Liu S, Ma G, Wang H, Yu G, Chen J, Song W. Medicine (Baltimore); 2022 Nov 18; 101(46):e31873. PubMed ID: 36401466 [Abstract] [Full Text] [Related]
6. Thymic epithelial tumor medical treatment: A narrative review. Huang Q, Zhu L, Liu Y, Zhang Y. Biochim Biophys Acta Rev Cancer; 2024 Sep 18; 1879(5):189167. PubMed ID: 39117091 [Abstract] [Full Text] [Related]
7. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. Jing X, Zhu H, Li Y, Jia W, Zhai X, Li J, Yu J. Immunotherapy; 2022 Oct 18; 14(14):1097-1107. PubMed ID: 36093721 [Abstract] [Full Text] [Related]
14. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. Girard N, Ponce Aix S, Cedres S, Berghmans T, Burgers S, Toffart AC, Popat S, Janssens A, Gervais R, Hochstenbag M, Silva M, Burger IA, Prosch H, Stahel R, Xenophontos E, Pretzenbaher Y, Neven A, Peters S. ESMO Open; 2023 Jun 18; 8(3):101576. PubMed ID: 37285717 [Abstract] [Full Text] [Related]
19. Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature. Wang F, Liu Y, Xu W, Zhang C, Lv J, Ma S. J Med Case Rep; 2021 Jul 06; 15(1):336. PubMed ID: 34225811 [Abstract] [Full Text] [Related]
20. Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis. Remon J, Villacampa G, Facchinetti F, Di Maio M, Marcuse F, Tiseo M, Hochstenbag M, Hendriks LEL, Besse B. Eur J Cancer; 2023 Feb 06; 180():117-124. PubMed ID: 36592506 [Abstract] [Full Text] [Related] Page: [Next] [New Search]